Dawei Sun
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 10%
- Circular RNAs in diseases
- RNA modifications and cancer
- Extracellular vesicles in disease
Papers in
-
- Circular RNAs in diseases 7
- DNA Repair Mechanisms 1
-
- MicroRNA in disease regulation 6
- Cancer-related molecular mechanisms research 6
- Cancer Genomics and Diagnostics 1
- Co-authors
- Junchen Hou (2 shared papers)Zhenling Ji (2 shared papers)Linhong Jiang (2 shared papers)Guo-yue Lv (6 shared papers)Lin An (5 shared papers)Guoyue Lv (8 shared papers)Fenghai Ren (3 shared papers)Xiaodong Sun (5 shared papers)
- Journals
- Frontiers in Oncology (3 papers)Clinica Chimica Acta (3 papers)Clinical & Translational Oncology (2 papers)Frontiers in Bioengineering and Biotechnology (1 paper)BioMed Research International (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Dawei Sun
33 papers receiving 1.8k citations
Dawei Sun's Hit Papers
Peers
Comparison fields: 5 of 96
- Cancer Research 822
- Molecular Biology 1.1k
- Oncology 271
- Hepatology 73
- Pathology and Forensic Medicine 57
Countries citing papers authored by Dawei Sun
This map shows the geographic impact of Dawei Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawei Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawei Sun more than expected).
Fields of papers citing papers by Dawei Sun
This network shows the impact of papers produced by Dawei Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawei Sun. The network helps show where Dawei Sun may publish in the future.
Co-authors
The 25 scholars most cited alongside Dawei Sun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CircRNA: a novel type of biomarker for cancer Hit paper breakdown → | 2017 | 632 |
| 2 | circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma Hit paper breakdown → | 2020 | 307 |
| 3 | 2017 | 105 | |
| 4 | 2018 | 85 | |
| 5 | 2020 | 67 | |
| 6 | 2020 | 62 | |
| 7 | 2019 | 61 | |
| 8 | 2015 | 52 | |
| 9 | 2015 | 51 | |
| 10 | 2017 | 38 | |
| 11 | 2022 | 34 | |
| 12 | Prognostic and clinicopathological significance of MACC1 expression in hepatocellular carcinoma patients: a meta-analysis. | 2015 | 33 |
| 13 | 2021 | 30 | |
| 14 | 2020 | 30 | |
| 15 | 2016 | 30 | |
| 16 | 2020 | 25 | |
| 17 | 2015 | 24 | |
| 18 | 2021 | 21 | |
| 19 | 2021 | 20 | |
| 20 | 2014 | 16 |
About Dawei Sun
Dawei Sun is a scholar working on Molecular Biology, Cancer Research, Oncology, Hepatology and Surgery, having authored 33 papers that have together received 1.8k indexed citations. Recurring topics across this work include Circular RNAs in diseases (7 papers), MicroRNA in disease regulation (6 papers), Cancer-related molecular mechanisms research (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), DNA Repair Mechanisms (1 paper), Ferroptosis and cancer prognosis (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Cancer Research (822 citations), Molecular Biology (1.1k citations), Oncology (271 citations), Hepatology (73 citations) and Pathology and Forensic Medicine (57 citations). Dawei Sun has collaborated with scholars based in China and United States. Frequent co-authors include Junchen Hou, Zhenling Ji, Linhong Jiang, Guo-yue Lv, Lin An, Guoyue Lv, Fenghai Ren, Xiaodong Sun, Shidong Xu and Jianlong Bu. Their work appears in journals such as Frontiers in Oncology, Clinica Chimica Acta, Clinical & Translational Oncology, Frontiers in Bioengineering and Biotechnology and BioMed Research International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.